Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Firebrick Pharma Limited ( (AU:FRE) ) has issued an update.
Firebrick Pharma Limited has announced a License and Distribution Agreement with Makans Limited to promote and sell its Nasodine Nasal Spray in Fiji and the South Pacific. This partnership, with Fiji’s largest pharmaceutical wholesaler, is expected to boost Nasodine’s market reach to a population of around two million, potentially increasing sales significantly. Makans will handle marketing, distribution, and regulatory requirements, paying Firebrick a handling fee and license fee per unit sold.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The company markets Nasodine Nasal Spray and has introduced it in the United States and Singapore, with other products in development.
YTD Price Performance: 37.10%
Average Trading Volume: 128,339
Technical Sentiment Consensus Rating: Sell
See more data about FRE stock on TipRanks’ Stock Analysis page.
